香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 （於開曼群島註冊成立的有限公司） 董事會召開日期 翰森製藥集團有限公司（「本公司」）董事會（「董事會」）茲通告謹定於二零二五年 八月十八日（星期一）舉行董事會會議，藉以（其中包括）考慮及通過本公司及其附 屬公司截至二零二五年六月三十日止的六個月中期業績及建議中期股息（如有）以 及處理其他事項。 承董事會命 翰森製藥集團有限公司 主席 鍾慧娟 香港，二零二五年八月六日 於本公告日期，董事會成員包括主席兼執行董事鍾慧娟女士、執行董事孫遠女士 及呂愛鋒博士；及獨立非執行董事林國強先生、陳尚偉先生及楊東濤女士。 （股份代號：3692） ...

Core Insights - The company is developing an IL23p19 inhibitor, QX004N, for the treatment of psoriasis (Ps) and Crohn's disease (CD) [1] - QX004N has recently entered Phase III clinical trials, marking it as the fourth product in the company's pipeline to reach this stage [1] - The company has signed an exclusive licensing agreement with Hansoh Pharmaceutical Group Co., Ltd. for the development, production, and commercialization of QX004N in mainland China, Taiwan, Hong Kong, and Macau [1] - The company received a total of RMB 58 million from Hansoh Pharmaceutical as milestone and other payments related to the Phase III trial [1]

Core Viewpoint - The company is developing an IL23p19 inhibitor, QX004N, for the treatment of psoriasis and Crohn's disease, and has entered into an exclusive licensing agreement with Hansoh Pharmaceutical for its development and commercialization in several regions [1] Group 1 - QX004N has recently entered Phase III clinical trials, marking it as the fourth product in the company's pipeline to reach this stage [1] - The company has received a total of RMB 58 million from Hansoh Pharmaceutical as milestone and other payments related to the Phase III trial [1]

Core Insights - The company is developing an IL23p19 inhibitor QX004N for the treatment of psoriasis (Ps) and Crohn's disease (CD) [1] - QX004N has recently entered Phase III clinical trials, marking it as the fourth product in the company's pipeline to reach this stage [1] - The company has signed an exclusive licensing agreement with Hansoh Pharmaceutical Group Co., Ltd. for the R&D, production, and commercialization of QX004N in mainland China, Taiwan, Hong Kong, and Macau [1] - The company received a total of RMB 58.0 million from Hansoh Pharmaceutical as milestone and other payments related to the Phase III trial of Ps [1]

Group 1 - The core viewpoint is that the liquidity and fundamentals of the Chinese healthcare industry continue to improve, maintaining a positive outlook for the healthcare sector [1] - The report indicates that the weak U.S. employment data may lead to heightened expectations for monetary easing in the second half of the year, suggesting an improved outlook for the industry [1] - The report highlights that the industry fundamentals are recovering, with a month-on-month increase in hospital prescription volumes in July, and significant profit growth expected in the third quarter due to the release of more innovative drugs [1] Group 2 - The company prefers leading large pharmaceutical firms and suggests avoiding companies overly reliant on biosimilars in the short term [2] - Selected stocks include: CSPC Pharmaceutical Group (01093), Sinopharm Group (01099), Hansoh Pharmaceutical (03692), and others [2] - The report emphasizes that the uncertainty in U.S. Treasury yields may prompt a reallocation of funds, further improving the liquidity of innovative drug assets [1]

里昂指出，行业基本面持续复苏，7月院内处方量环比提升，随着更多创新药放量，第三季行业盈利有 望实现显著增长，加上美债不确定性可能促使资金重新配置，进一步改善创新药资产流动性，相信行业 拐点已过，未来将迎来盈喜等正面催化剂。 该行偏好领先大型药厂，短期而言避开过度依赖生物仿制药的公司。该行选股包括石药集团(01093)、 新诺威(300765.SZ)、翰森制药(03692)、爱尔眼科(300015.SZ)、恒瑞医药(01276,600276.SH)、康方生物 (09926)、中生制药(01177)、国药控股(01099)、康哲药业(00867)、大参林(603233.SH)、华东医药 (000963.SZ)、泰格医药(03347)及药明康德(02359)。 智通财经APP获悉，里昂发布研报称，中国医疗健康行业流动性及基本面持续改善，维持对医疗健康板 块正面看法，指出美国就业数据疲软或市场对下半年货币宽松预期急升温，预示着行业下半年改善前 景，相信特朗普再提最惠国药品定价政策及安徽启动生物类似药集中采购，对行业影响则相对有限。 ...

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 公司名稱: 翰森製藥集團有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03692 | 說明 | - | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.00001 | HKD | | 200,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.00001 | HKD | | 200,000 | 本月底法定/ ...

Core Insights - JD Health and Hansoh Pharmaceutical are deepening their collaboration, with Hansoh's new pulmonary hypertension drug, Silapad, set for exclusive online launch on JD Health's platform [1][3] - The partnership aims to enhance drug accessibility for pulmonary hypertension patients and leverage JD Health's channel advantages for market coverage [1][3] Summary by Sections Collaboration Details - The collaboration will expand into multiple fields, including anti-infection and respiratory health, with JD Health enhancing patient medication adherence through professional services [3] - In the second half of 2025, Hansoh will deepen cooperation in metabolism and oncology areas on JD Health's platform [3] Product Launch and Services - Hansoh plans to launch more core products on JD's self-operated channels, prioritizing innovative drugs for exclusive online release [3] - The partnership will create a closed-loop service from online consultations to drug delivery, utilizing JD's internet hospital and pharmacy capabilities [3] Strategic Importance - Hansoh's collaboration with JD Health is a key part of its strategic transformation, aiming to manage the full cycle from product development to patient service [3] - Both companies emphasize the importance of patient needs and aim to improve the accessibility of innovative drugs and comprehensive health management solutions [3]

港股创新药概念多股走强，歌礼制药(01672.HK)、石药集团(01093.HK)涨近3%，中国生物制药 (01177.HK)涨超2%，百济神州(06160.HK)、翰森制药(03692.HK)等跟涨。 ...

Core Viewpoint - Southbound capital has significantly increased its investment in the Hong Kong stock market this year, leading to a historical net inflow of over 840 billion HKD, surpassing previous records and contributing to a strong performance in the market [1][2]. Group 1: Southbound Capital Inflows - As of July 29, 2023, southbound capital has recorded a cumulative net inflow of 8420.02 billion HKD, marking a historical high for the year and more than double the inflow of the same period in 2024 [1][2]. - The daily net inflow peaked on April 9, 2023, with 355.86 billion HKD, setting a record for single-day inflows [1]. - In 135 trading days this year, there were net inflow days on 114 occasions, accounting for over 80% of the trading days [1]. Group 2: Market Performance - The Hang Seng Index has risen over 27% year-to-date, while the Hang Seng Technology Index has increased by over 26% [1][3]. - Major stocks with market capitalizations exceeding 1 trillion HKD have all seen gains, with Xiaomi Group-W up over 60% and Tencent Holdings up over 34% [1][4]. - The Hong Kong stock market has outperformed major global markets, with the Hang Seng Index, Hang Seng China Enterprises Index, and Hang Seng Technology Index showing respective increases of 27.24%, 25.46%, and 26.33% [3]. Group 3: Sector and Stock Performance - Southbound capital has heavily invested in the financial, information technology, and consumer discretionary sectors, with holdings valued at 14517.43 billion HKD, 11115.84 billion HKD, and 7175.67 billion HKD respectively [2][3]. - Notable individual stock holdings include Tencent Holdings at over 5400 billion HKD, and other significant investments in China Mobile, Xiaomi Group-W, and Alibaba-W, each exceeding 2000 billion HKD [2][3]. Group 4: Valuation and Future Outlook - The rolling P/E ratio of the Hang Seng Index has increased to 10.49 times, up from 8.96 times at the beginning of the year, indicating a rise in market valuation [5][6]. - Analysts predict that southbound capital inflows could exceed 1 trillion HKD for the year, although the pace may slow in the second half [6][7]. - The overall market sentiment remains positive, with expectations of continued upward movement supported by improved fundamentals and ongoing capital inflows [6][7].